JPRN-UMIN000037697
Recruiting
未知
Diagnostic Performance of PET Imaging for Prostate Specific Membrane Antigen (PSMA) - Diagnostic Performance of PSMA-PET
ConditionsProstate cancer
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Prostate cancer
- Sponsor
- Osaka University Graduate School of Medicine
- Enrollment
- 250
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •(1\) Patient who cannot keep the body position for 30 minutes. (2\) Others who are regarded as unsuitable for enrollment in the opinion of research staff.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
Imaging of the prostate tumors using PET/CT and PET/MRI with the ligand of the prostatic specific membrane antigene 68Ga-PSMA-11prostatic carcinoma higly suspected or its staging or restagingTherapeutic area: Diseases [C] - Male diseases of the urinary and reproductive systems [C12]EUCTR2017-004128-32-CZFakultní nemocnice Plzen200
Recruiting
Not Applicable
Evaluation of new PET tracer, [F-18]Florastamin for diagnosing prostate cancer: Phase I clinical trialKCT0004817FutureChem10
Recruiting
Not Applicable
Diagnostic performance of Prostate HistoScanningTM (PHS) in men at risk of prostate cancer scheduled for an initial prostate biopsy.Subjects suspected to have PCa who are schedules for a first prostate biopsy.C61Malignant neoplasm of prostateDRKS00005263Advanced Medical Diagnostics SAWaterloo Office Park Bât i bte 3391
Recruiting
Not Applicable
Evaluation of new PET tracer, [F-18]Florastamin for diagnosing prostate cancerNeoplasmsKCT0003924Korea Cancer Center Hospital6
Active, not recruiting
Phase 1
18F-PSMA PET in primary prostate cancer.75 patients with the suspicion on PCa (elevated PSA and/or abnormal digital rectal exam) will receive a PSMA-PET following mpMRI. 25 patients with PIRADS 1-2 (probably benign disease), 25 patients with PIRADS 3 (equivocal disease) and 25 patients with PIRADS 4-5 (highly suspicious for malignancy) will be included in this explorative study.MedDRA version: 20.0Level: LLTClassification code 10036921Term: Prostate carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10060862Term: Prostate cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2020-001387-28-NLRadboud University Medical Center75